EPAZ yields 7692.31% · ABBV yields 3.06%● Live data
📍 EPAZ pulled ahead of the other in Year 1
Combined, EPAZ + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of EPAZ + ABBV for your $10,000?
Epazz, Inc., together with its subsidiaries, designs and sells various software programs to business enterprises, hospitals, and government and post-secondary institutions in the United States. It offers EPAZZ BoxesOS v3.0, a Web portal infrastructure operating system that integrates with each organization's back-end systems and provides a customizable personal information system for various stakeholders, including students, faculty, alumni, employees, and clients. The company also provides AutoHire software, an interactive question, and online screening and ranking system; and Desk Flex software that allow businesses make use of office space restrictions by enabling employees to instantly access their workstation tools from various areas in and outside of the office. In addition, it offers Agent Power software, which provides information and tools for call centers to help enhance their workforce management; Integrated Plant Management Control software, a software system design for water and wastewater facility management; and CHMCi, an enterprise solution that includes tools to provide, manage, bill, and track behavioral healthcare and social services. Further, the company provides K9 Bytes, a point of sale (POS) software for pet care applications, such as pet boarding; daycare; grooming; training; and other pet care services, including dog walking and pet sitting. Its K9 Bytes products include scheduling, billing, retail inventory, and general POS capabilities comprising credit and debit card processing, collar printers, digital signature tablets, and biometric/fingerprint identification hardware. Epazz, Inc. was founded in 2000 and is headquartered in Chicago, Illinois.
Full EPAZ Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.